Guildford, UK, 23 November 2009: ReNeuron Group plc (LSE: RENE.L) today announces that it will report its interim results for the six months ending 30 September 2009 on Thursday 26 November 2009. A conference call for analysts will be held at 9.30 GMT on that day. For further information, please contact Juliet Edwards on the number below.

Enquiries: ReNeuron Michael Hunt, Chief Executive Officer Tel: +44 (0) 1483 302560 Financial Dynamics Juliet Edwards Tel: +44 (0) 20 7269 7125

About ReNeuron

ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has received regulatory and conditional ethical approvals to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina. ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell® products for use in academic and commercial research. The Company’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation. ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at